YCH2823
YCH2823 is an inhibitor of USP7 (IC50 = 49.6 nM; Kd = 0.117 μM) . YCH2823 shows significant efficacy in inhibiting TP53 wild-type and mutant tumors, with approximately 5-fold higher potency than FT671. YCH2823 induce apoptosis. YCH2823 synergistic effects with mTOR inhibitors[1].
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Deubiquitinase
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/ych2823.html
Concentration
10mM
Purity
99.87
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
COC1=CC=C(C=C1)N2C=CC3=C2N=CN(C3=O)CC4(CCN(CC4)C(C[C@H](C5=CC=CC=C5)C)=O)O
Molecular Formula
C29H32N4O4
Molecular Weight
500.59
References & Citations
[1]Yong-Jun C et al. Identification of YCH2823 as a novel USP7 inhibitor for cancer therapy Elsevier Inc.. 2024 Apr 116071.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
USP7
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Carcinoembryonic Antigen (CEA, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5, CEACAM5, CD66e, CD66e Antigen, Meconium Antigen 100) (MaxLight 490)
Carcinoembryonic Antigen (CEA, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5, CEACAM5, CD66e, CD66e Antigen, Meconium Antigen 100) (MaxLight 490)
DNAJA4 (DnaJ Homolog Subfamily A Member 4, MST104, MSTP104, PRO1472) (FITC)
